Abstract:Febuxostat, a new xanthine oxidase (XO) inhibitor, could become the
standard for managing uric acid levels in patients with chronic kidney disease (CKD).
However, little has been reported regarding patients with severe renal impairment.
Further, the conversion rate for switching patients from allopurinol to febuxostat
remains unknown.
We studied 65 CKD patients being administered allopurinol for hyperuricemia and then
switched them to febuxostat at a conversion ratio of 100 mg allopurinol: 10 mg
febuxostat. S… Show more
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.